News & Updates

Childhood maternal warmth shapes adolescents’ mental health through social safety

Early-life maternal warmth shapes adolescents’ mental and physical health, with perceptions of social safety mediating this effect, the Millennium cohort study has shown.

Innovative biodegradable biohybrid targeted therapy for intracranial tumours

The world’s first magnetically driven nonimmunogenic blood hydrogel fibre robot for treatment of deep-seated brain tumours have been successfully developed by a collaborative research team from the Chinese University of Hong Kong (CUHK), the Shenzhen University and the Shenzhen Institutes of Advanced Technology (SIAT).

Cough variant asthma: A diagnostic challenge with a simple solution

Long-term rectal cancer outcomes better with laparoscopic vs robotic surgery

Three-year data from the REAL study has shown that robot-assisted resection of middle or low rectal cancer is associated with lower locoregional recurrence and disease-free survival compared with the conventional laparoscopic approach.

V-ERAT trumps antibiotics for uncomplicated acute appendicitis

Patients with uncomplicated acute appendicitis may opt for visual endoscopic retrograde appendicitis therapy (V-ERAT) as a safe and effective alternative to antibiotic treatment to reduce the risk of recurrence, according to a study.

Is social media a reliable source of paediatric drug information?

Using social media to obtain relevant information is possible, with a recent study suggesting that data from child-rearing public parenting forums (CPPFs) may aid in assessing paediatric adverse drug events and in detecting unknown adverse drug reactions (ADRs) and medication errors.

HDL levels linked to AMD risk

Both high and low levels of high-density lipoprotein (HDL) are significantly associated with an elevated risk of age-related macular degeneration (AMD), reveals a study.

Efruxifermin misses mark in MASH-related compensated cirrhosis

Treatment with the bivalent fibroblast growth factor 21 (FGF21) analogue efruxifermin falls short of improving fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction–associated steatohepatitis (MASH), according to a phase 2b study.